A Linear 19-Mer Plant Defensin-Derived Peptide Acts Synergistically with Caspofungin against Candida albicans Biofilms

Cools, Tanne; Struyfs, Caroline; Drijfhout, Jan W.; Kucharíková, Soňa; Romero, Celia Lobo; Dijck, Patrick Van; Ramada, Marcelo Henrique Soller; Bloch, Carlos; Cammue, Bruno P. A.; Thevissen, Karin

doi:10.3389/fmicb.2017.02051

Cited by 35 publications

(25 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also suggested that this defensin may also be involved in the inhibition of yeast-to-hypha transition, but the mechanism of this process remained undefined. Similar observations were described in another report, indicating a synergistic action of a smaller linear HsAFP1-derived peptide (HsLin06_18) with several echinocandins (caspofungin, micafungin and anidulafungin) against C. albicans [ 107 ]. These substances also significantly reduced in vitro biofilm formation on catheters by C. glabrata and caspofungin-resistant C. albicans strains.…”

Section: A New Perspective For Plants’ Components In Antifungal Thsupporting

confidence: 86%

Plant-Derived Substances in the Fight Against Infections Caused by Candida Species

Guevara-Lora

Bras

Karkowska‐Kuleta

et al. 2020

IJMS

View full text Add to dashboard Cite

Yeast-like fungi from the Candida genus are predominantly harmless commensals that colonize human skin and mucosal surfaces, but under conditions of impaired host immune system change into dangerous pathogens. The pathogenicity of these fungi is typically accompanied by increased adhesion and formation of complex biofilms, making candidal infections challenging to treat. Although a variety of antifungal drugs have been developed that preferably attack the fungal cell wall and plasma membrane, these pathogens have acquired novel defense mechanisms that make them resistant to standard treatment. This causes an increase in the incidence of candidiasis and enforces the urgent need for an intensified search for new specifics that could be helpful, alone or synergistically with traditional drugs, for controlling Candida pathogenicity. Currently, numerous reports have indicated the effectiveness of plant metabolites as potent antifungal agents. These substances have been shown to inhibit growth and to alter the virulence of different Candida species in both the planktonic and hyphal form and during the biofilm formation. This review focuses on the most recent findings that provide evidence of decreasing candidal pathogenicity by different substances of plant origin, with a special emphasis on the mechanisms of their action. This is a particularly important issue in the light of the currently increasing frequency of emerging Candida strains and species resistant to standard antifungal treatment.

show abstract

Section: A New Perspective For Plants’ Components In Antifungal Thsupporting

confidence: 86%

Plant-Derived Substances in the Fight Against Infections Caused by Candida Species

Guevara-Lora

Bras

Karkowska‐Kuleta

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition to the SMIC, the BIC-2 (BIC 50 ), is the minimum compound concentration resulting in a 2-fold inhibition of biofilm formation. Similarly, the BEC-2 (BEC 50 ) is the minimum compound concentration resulting in a 2-fold eradication of mature biofilms 92 93 . In practice, to assess biofilm inhibition, compounds are included during the biofilm growth phase.…”

Section: Methods For Antifungal Susceptibility Testing Of Biofilmsmentioning

confidence: 99%

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Dijck¹,

Sjollema²,

Cammue³

et al. 2018

Microb Cell

Self Cite

View full text Add to dashboard Cite

Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

show abstract

“…The diversity of synthetic peptides entering clinical trials has increased over the last 13 years, stimulating advances in Fmoc SPPS technologies in response to the growing demand for medicinal chemistry and pharmacology (Behrendt et al, 2016). Several groups have synthesized linear (Tran et al, 2008;Magliani et al, 2011;Konno et al, 2015;Cools et al, 2017;Park et al, 2018) and cyclic peptides (Mosca et al, 2000;Schaaper et al, 2001;Konno et al, 2015;Ng-Choi et al, 2019) using Fmoc SPPS.…”

Section: Chemical Synthesismentioning

confidence: 99%

Antifungal Peptides as Therapeutic Agents

Ullivarri

Arbulu

García-Gutiérrez

et al. 2020

Front. Cell. Infect. Microbiol.

175

132

View full text Add to dashboard Cite

Fungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency-and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.

show abstract

A Linear 19-Mer Plant Defensin-Derived Peptide Acts Synergistically with Caspofungin against Candida albicans Biofilms

Cited by 35 publications

References 45 publications

Plant-Derived Substances in the Fight Against Infections Caused by Candida Species

Plant-Derived Substances in the Fight Against Infections Caused by Candida Species

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Antifungal Peptides as Therapeutic Agents

Contact Info

Product

Resources

About